1. Germline BRCA1/2 variant analysis for individuals with metastatic castrate-resistant prostate cancer (mCRPC; See Policy Guidelines) to select treatment with FDA-approved targeted therapies or immunotherapy may be considered medically necessary.

2. All other uses of germline BRCA1/2 variant analysis to guide prostate cancer targeted therapy or immunotherapy are considered investigational.

3. Somatic testing using tissue biopsy for homologous recombination repair (HRR) gene alterations (BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L) to select treatment for mCRPC with FDA-approved targeted therapies or immunotherapy may be considered medically necessary. (Note: Testing for HRR gene mutations is not the same as HRD—Homologous Recombination Deficiency—associated with ovarian cancer) See Policy Guidelines. For comprehensive tumor testing panels, see Blue Shield of California Medical Policy: Oncology: Molecular Analysis Of Solid Tumors And Hematologic Malignancies.

4. All other uses of somatic testing for HRR gene alterations to guide prostate cancer targeted therapy or immunotherapy are considered investigational.

5. Tumor testing for microsatellite instability (MSI) or deficient mismatch repair (dMMR; MSH 2, MSH 6, PMS 2 and MLH 1) to select treatment for unresectable or metastatic prostate cancer with FDA-approved targeted therapies or immunotherapy (e.g., pembrolizumab/Keytruda) may be considered medically necessary. See Policy Guidelines.

6. All other uses of tumor testing for MSI or dMMR to guide prostate cancer targeted therapy or immunotherapy are considered investigational.

NOTE: Refer to Appendix A to see the policy statement changes (if any) from the previous version.

Policy Guidelines

Note: This policy is not intended to address germline testing related to determining the risk of developing cancer. See instead: 2.04.02 Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2)

Androgen deprivation therapy (ADT) is usually the initial treatment for patients with advanced prostate cancer. Disease that progresses while the patient is on ADT is referred to a castration-resistant prostate cancer.

HRR testing vs. HRD: Homologous recombination occurs in early cell division when homologous chromosomes pair up. There are a lot of DNA breaks during this process, which HRR fixes similar to the MisMatch Repair (MMR) genes. MMR has to do with smaller breaks or changes with nucleotides. Both repair the normally occurring DNA breaks that minimize mutations. When absent or deficient, more mutations occur which can lead to cancer. HRR gene mutations (beyond BRCA) are not interchangeable with genomic instability. There are about 14 HRR genes, and 4 common MMR
genes. The HRR pathway is sometimes referred to as the PARP pathway. HRR mutations are an indication for PARP inhibitor (e.g., Olaparib/Lynparza) treatment.

Homologous recombination deficiency (HRD) is a similar tumor characteristic that is defined by the inability to accurately repair double-strand breaks (DSBs) in DNA via homologous recombination. HRD can be accessed via 2 different types of biomarkers. In ovarian cancers, these include individual mutations in BRCA1 or BRCA2 and the assessment of genomic instability (Loss of Heterozygosity or LOH, Large-scale State Transitions or LST and Telomeric Allelic Imbalance or TAI). Genomic instability, or large-scale structural rearrangements to chromosomes, results in specific measurable genomic aberrations and serves as the "collateral damage" that can occur to the genome as a result of HRD. Tumor samples that have individual BRCA1/2 mutations or markers of genomic instability are characterized as HRD positive. HRD testing is done routinely for ovarian cancer.

MSI/dMMR: Microsatellites are small repeat sequences in non-coding DNA, usually 2-7 nucleotides. A simple PCR test can identify them. MMR genes (e.g., MSH2, MSH6, PMS2, and MHL1) function to repair these insertions and deletions (indels). When MMR genes are deficient (dMMR), the microsatellites become more frequent or unstable (MSI-H). dMMR can be checked using IHC (ImmunoHisto Chemistry) that looks for absence of the normal proteins produced by the MMR genes, or by looking for mutations in the genes. dMMR usually leads to MSI-H.

This policy does not address NTRK testing. The use of tropomyosin receptor kinase (TRK) inhibitors for individuals with neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors is addressed separately in evidence review 5.01.31.

Testing for individual genes (not gene panels) associated with FDA-approved therapeutics (i.e., as companion diagnostic tests) for therapies with National Comprehensive Cancer Network (NCCN) recommendations of 2A or higher are not subject to extensive evidence review. Note that while the FDA approval of companion diagnostic tests for genes might include tests that are conducted as panels, the FDA approval is for specific genes (such as driver mutations) and not for all of the genes on the test panel.

For guidance on testing criteria between policy updates, refer to the FDA’s List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools) (https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools) for an updated list of FDA-approved tumor markers and consult the most current version of NCCN management algorithms.

**Repeat Genomic Testing**

There may be utility in repeated testing of gene variants for determining targeted therapy or immunotherapy in individuals with prostate cancer, as tumor molecular profiles may change with subsequent treatments and re-evaluation may be considered at time of cancer progression for treatment decision-making (See NCCN PROS-B 3 of 3). The American Society of Clinical Oncology (ASCO) currently suggests repeat genomic testing for individuals on targeted therapy with suspected acquired resistance, especially if choice of next-line therapy would be guided. The ASCO guidance is not tumor specific, and it cautions to consider clinical utility (Chakravarty et al, 2022; PMID 35175857).

**Paired Somatic-Germline Testing**

Testing for genetic changes in tumor tissue assesses somatic changes. Some somatic testing involves a paired blood analysis in order to distinguish whether findings in tumor tissue are acquired somatic changes or germline changes. Some laboratories offer paired tumor sequencing and germline sequencing which is done at the same time and in the same laboratory. The goal of this paired testing is to identify truly somatic changes to guide treatment. However, paired testing can also
identify potential germline changes that might indicate an inherited cancer syndrome. These results would need to be confirmed through germline testing if personal and family cancer history is consistent with an inherited cancer syndrome (see policies related to inherited cancer syndromes, 2.04.02, 2.04.08, 2.04.88, 2.04.101).

Paired genetic testing is different than concurrent somatic-germline testing. In concurrent testing, the germline results are not used to filter the somatic results. Rather, the laboratories perform large, separate panels of germline and somatic variants. The goal is to identify options for genome-informed treatment and to identify hereditary cancer risk. For concurrent panel testing, see evidence review 2.04.93 - Genetic Cancer Susceptibility Panels Using Next Generation Sequencing for germline panel, and see Blue Shield of California Medical Policy: Oncology: Molecular Analysis Of Solid Tumors And Hematologic Malignancies.

Concurrent Somatic Liquid-based and Tissue-based Genomic Testing
Liquid biopsy testing uses blood samples and assesses cancer DNA and non-cancer DNA in the same blood sample. The goal is to identify options for genome-informed treatment. Some providers will order a liquid biopsy test and a tissue biopsy test at the same time, not for filtering or for comparison as in the paired genetic testing section above, but to hasten time to treatment. If the intent of concurrent testing is to follow an individual over time for resistance mutations/response to therapy, then consideration could be given to doing liquid biopsy at diagnosis with the tissue biopsy to make sure that whatever mutations are going to be followed longitudinally can be detected by the liquid biopsy. For example, monitoring of *BRCA* mutation evolution (reversion mutations) in individuals with prostate cancer during poly adenosine diphosphate-ribose polymerase (PARP) inhibitor therapy may be achieved with serial circulating tumor DNA (ctDNA) sampling, and allow for earlier detection of resistance and selection of alternative therapies to reduce the risk of resistance (Goodall et al, 2017; PMID 28450425). This testing strategy has not been fully studied, and is not yet discussed in the NCCN guidelines for prostate cancer. For circulating tumor DNA (liquid biopsy), see Blue Shield of California Medical Policy: Oncology: Circulating Tumor DNA and Circulating Tumor Cells (Liquid Biopsy).

Genetics Nomenclature Update
The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society’s nomenclature is recommended by the Human Variome Project, the Human Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology - “pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign” - to describe variants identified that cause Mendelian disorders.

<table>
<thead>
<tr>
<th>Previous</th>
<th>Updated</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutation</td>
<td>Disease-associated variant</td>
<td>Disease-associated change in the DNA sequence</td>
</tr>
<tr>
<td>Variant</td>
<td></td>
<td>Change in the DNA sequence</td>
</tr>
<tr>
<td>Familial variant</td>
<td>Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives</td>
<td></td>
</tr>
</tbody>
</table>
Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

<table>
<thead>
<tr>
<th>Variant Classification</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathogenic</td>
<td>Disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Likely pathogenic</td>
<td>Likely disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Variant of uncertain significance</td>
<td>Change in DNA sequence with uncertain effects on disease</td>
</tr>
<tr>
<td>Likely benign</td>
<td>Likely benign change in the DNA sequence</td>
</tr>
<tr>
<td>Benign</td>
<td>Benign change in the DNA sequence</td>
</tr>
</tbody>
</table>

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

Genetic Counseling
Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Description

Biomarker-targeted therapy has shown a clear survival benefit in individuals with metastatic prostate cancer. More recently, testing for tumor mutational burden (TMB) status to select individuals for immunotherapy has been proposed. Typically, the evaluation of biomarker status requires tissue biopsy. Circulating tumor DNA (ctDNA) or circulating tumor cell testing (also known as liquid biopsy) is proposed as a non-invasive alternative.

Related Policies

- Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2)
- Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
- Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management
- Germline and Somatic Biomarker Testing for Targeted Treatment and Immunotherapy in Breast Cancer
- Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
- Molecular Analysis for Targeted Therapy or Immunotherapy of Non-Small-Cell Lung Cancer
- Genetic Cancer Susceptibility Panels Using Next Generation Sequencing
- Oncology: Molecular Analysis Of Solid Tumors And Hematologic Malignancies
- Oncology: Circulating Tumor DNA and Circulating Tumor Cells (Liquid Biopsy)

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract
language will control. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

### Regulatory Status

Table 1 summarizes the targeted treatments approved by the FDA for patients with prostate cancer, along with the approved companion diagnostic tests. The information in Table 1 was current as of August 15, 2022. An up-to-date list of FDA cleared or approved companion diagnostics is available at https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools. The table does not include NTRK testing.

#### Table 1. Targeted Treatments for Metastatic Prostate Cancer and FDA Approved Companion Diagnostic Tests

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Indication in Prostate Cancer</th>
<th>Companion Diagnostic</th>
<th>Biomarkers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Targeted Treatment for Prostate Cancer</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olaparib (Lynparza)</td>
<td>Adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved</td>
<td>BRACAnaly sis CDx (Myriad Genetic Laboratories, Inc.)</td>
<td><em>BRCA1</em> and <em>BRCA2</em> Mutations</td>
</tr>
<tr>
<td></td>
<td>Homologous recombination repair (HRR) genes: <em>BRCA1</em>, <em>BRCA2</em>, <em>ATM</em>, <em>BARD1</em>, <em>BRIPI</em>, <em>CDK12</em>, <em>CHEK1</em>, <em>CHEK2</em>, <em>FANCL</em>, <em>PALB2</em>, <em>RAD51B</em>, <em>RAD51C</em>, <em>RAD51D</em>, and <em>RAD54L</em> alterations</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FoundationOne Liquid CDx (Foundation Medicine, Inc.)</td>
<td></td>
<td><em>BRCA1</em>, <em>BRCA2</em>, and <em>ATM</em> alterations</td>
</tr>
</tbody>
</table>

Reproduction without authorization from Blue Shield of California is prohibited
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Indication in Prostate Cancer</th>
<th>Companion Diagnostic</th>
<th>Biomarkers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rucaparib</strong></td>
<td>Adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.</td>
<td>FoundationOne Liquid CDx (Foundation Medicine, Inc.)</td>
<td>BRCA1 and BRCA2 alterations</td>
</tr>
</tbody>
</table>

| **Immunotherapy for Solid Tumors** | | | |
| Pembroizumab (Keytruda) | Adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options | Foundation One CDx (Foundation Medicine, Inc.) | Microsatellite instability-High (MSI-H) |
| | Adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (≥10 mutations/mega base) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no | Foundation One CDx (Foundation Medicine, Inc.) | TMB ≥ 10 mutations per megabase |
Germline and Somatic Biomarker Testing for Targeted Treatment and Immunotherapy in Prostate Cancer (BRCA1/2, Homologous Recombination Repair Gene Alterations, Microsatellite Instability/Mismatch Repair, Tumor Mutational Burden)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Indication in Prostate Cancer</th>
<th>Companion Diagnostic</th>
<th>Biomarkers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>satisfactory alternative treatment options</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sources: Food and Drug Administration (2022);6, Drugs@FDA7

Rationale

Background
Homologous Recombination Repair (HRR) Gene Alterations (BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L) to Guide Treatment

DNA damage happens daily, and most are repaired to allow normal cell functioning. Double strand breaks (DSB) in the DNA are particularly damaging. Repair of DSB utilizes the homologous recombination repair (HRR) pathway. Many types of cancer, however, are unable to repair DNA damage. This leads to the accumulation of genetic errors, such as loss of DNA, rearrangements in the DNA, and loss of entire genes. The consequence of these errors is genomic instability. The loss of the HRR and associated genomic instability is called homologous recombination deficiency (HRD). HRD is associated with several types of cancer including prostate cancer, where estimates as high as 30% of metastatic castrate-resistant prostate cancer (mCRPC) tumors have genetic changes that result in the loss of DNA repair capacity.1

Friends of Cancer Research convened a consortium addressing the lack of consistency in the way HRD is defined and measurement methods.2 They proposed the following definition: “HRD is a phenotype that is characterized by the inability of a cell to effectively repair DNA double-strand breaks using the HRR pathway.” Additionally, they encourage the use of “HRD” and “HRP” to reflect homologous recombination deficiency and homologous recombination proficiency. While the consortium did not explicitly define how to measure homologous recombination repair status, they acknowledge that it might involve gene variant testing as well as genomic instability measurement and call for transparency and standardization.

Specific to prostate cancer, the National Comprehensive Cancer Network (NCCN) prostate cancer guideline gives examples of HRR genes which are a subset of the 14 genes approved by the FDA (BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L), and acknowledges the 14 HRR genes for determining eligibility for olaparib.3

Mismatch Repair Deficiency/Microsatellite Instability
Mismatch repair deficiency (dMMR) and high levels of microsatellite instability (MSI-H) describe cells that have alterations in certain genes involved in correcting errors made when DNA is replicated. dMMR tumors are characterized by a high tumor mutational load and potential responsiveness to anti-PD-L1-immunotherapy. MMR deficiency is most common in colorectal cancer, other types of gastrointestinal cancer, and endometrial cancer, but it may also be found in other cancers including prostate cancer. Microsatellite instability testing is generally performed using polymerase chain reaction (PCR) for 5 biomarkers, although other biomarker panels and next generation sequencing (NGS) are sometimes performed. High microsatellite instability is defined as 2 or more of the 5 biomarkers showing instability or more than 30% of the tested biomarkers showing instability depending on what panel is used. Microsatellite instability testing is generally paired with immunohistochemistry (IHC) assessing lack of protein expression from 4 DNA mismatch repair genes thereby reflecting dMMR.4
Literature Review
Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

Biomarker Testing Using Tissue Biopsy to Select Targeted Treatment
Clinical Context and Test Purpose
Prostate cancer treatment selection is informed by tumor type, grade, stage, patient performance status and preference, prior treatments, and the molecular characteristics of the tumor such as the presence of driver mutations. One purpose of biomarker testing of patients who have advanced cancer is to inform a decision regarding treatment selection (e.g., whether to select a targeted treatment or standard treatment).

The question addressed in this evidence review is: Does biomarker testing of tumor tissue for BRCA1/2 or homologous repair deficiency, or germline testing for BRCA 1/2 variants improve the net health outcome in individuals with prostate cancer?

This policy does not review circulating tumor DNA and circulating tumor cells (liquid biopsy).

Note that this policy does not review NTRK gene fusions; The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is individuals with prostate cancer for whom the selection of targeted treatment depends on the molecular characterization of the tumor.

Interventions
The technologies being considered are germline BRCA1/2 variant testing, or somatic testing for homologous recombination repair (HRR) gene alterations (BRCA1, BRCA2, ATM, BARD1, BRIPI, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L), and tumor testing for microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) to guide treatment.

Comparators
Decisions about treatment in prostate cancer are based on clinical characteristics. The comparator would be no variant testing to guide treatment.

Outcomes
The general outcomes of interest in oncology are overall survival (OS), disease-specific survival, quality of life (QOL), treatment-related mortality and morbidity.

Beneficial outcomes resulting from a true-positive test result are prolonged survival, reduced toxicity, and improved QOL associated with receiving a more effective targeted therapy. Beneficial outcomes from a true negative result are prolonged survival associated with receiving chemotherapy in those without driver mutations.
Harmful outcomes resulting from a false-negative test result include shorter survival from receiving less effective and more cytotoxic chemotherapy in those with driver mutations; possible harmful outcomes resulting from a false-positive test result are a shorter survival from receiving potentially ineffective targeted treatment and delay in initiation of chemotherapy in those without driver mutations.

The overall response rate (ORR) may be used as a surrogate endpoint reasonably likely to predict clinical benefit in patients with refractory solid tumors. ORR can be measured by the proportion of patients with best overall confirmed response of complete response) or partial response by the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), or Response Assessment in Neuro-Oncology criteria, as appropriate by a blinded and independent adjudication committee. There are clearly defined quantitative thresholds for the follow-up of patients in oncology trials. A general rule is a continuation of treatment until disease progression or unacceptable toxicity. Long-term follow-up outside of a study setting is conducted to determine survival status. The duration of follow-up for the outcomes of interest is 6 months and 1 year.

**Study Selection Criteria**
Methodologically credible studies were selected using the following principles:
- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for randomized controlled trials (RCTs);
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Testing for individual genes (not gene panels) associated with FDA-approved therapeutics (ie, as companion diagnostic tests) for therapies with National Comprehensive Cancer Network (NCCN) recommendations of 2A or higher are not subject to extensive evidence review. Note that while the FDA approval of companion diagnostic tests for genes might include tests that are conducted as panels, the FDA approval is for specific genes (such as driver mutations) and not for all of the genes on the test panel.

**Clinically Valid and Clinically Useful**
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse). A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

**Review of Evidence**
Clinical trials have evaluated the effectiveness of poly adenosine diphosphate-ribose polymerase (PARP) inhibitor drugs in individuals with prostate cancer confirmed to have a BRCA1, BRCA2, or ATM alteration. Summarized below are the pivotal trials that supported the BRCA variant-related FDA-approved indications in prostate cancer.

**Olaparib**
Hussain et al (2020) published results from the open-label, multicenter, phase 3 PROfound trial (NCT02987543), which randomized individuals with metastatic castration-resistant prostate cancer (mCRPC) and disease progression following prior treatment with a next-generation hormonal agent to treatment with olaparib 300 mg twice daily (n=256) or investigator’s choice of enzalutamide or abiraterone acetate plus prednisone (n=131). Study participants were divided into 2 cohorts based on their HRR gene mutation status. Specifically, individuals with mutations in BRCA1, BRCA2,
or ATM were randomized to cohort A (n=245) and those with mutations in 12 other HRR pathway genes (BRIPI, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L) were randomized to cohort B (n=142). Participants with co-mutations were assigned to cohort A. The primary efficacy outcome was radiological progression-free survival (rPFS) in cohort A, which demonstrated a statistically significant improvement for olaparib compared to control with a median rPFS of 7.4 months versus 3.6 months (hazard ratio [HR], 0.34; 95% confidence interval [CI], 0.25 to 0.47; \( p < 0.0001 \)). The median duration of OS in cohort A was 19.1 months with olaparib and 14.7 months with control therapy (HR, 0.69; 95% CI, 0.50 to 0.97; \( p = 0.02 \)). In cohort B, the median duration of OS was 14.1 months with olaparib and 11.5 months with control therapy. In the overall population (cohorts A and B), the corresponding durations were 17.3 months and 14.0 months.

**Rucaparib**

Abida et al (2020) published results from the phase 2, multi-center, single-arm clinical trial of rucaparib in individuals with BRCA-mutated mCRPC that supported its accelerated FDA approval in 2020 (TRITON2). This trial enrolled 115 participants who were treated with rucaparib 600 mg twice daily. For the efficacy population, median treatment duration was 8.1 months and median follow-up was 17.1 months. The primary endpoint of objective response rate, which was rated by blinded, independent radiology review, was 43.5% (95% CI, 31.0% to 56.7%). Median rPFS duration was 9.0 months (95% CI, 8.3 to 13.5). Anemia was the most frequent grade 3 or higher adverse event (25.2%). A key limitation of this trial is its lack of a control group. Continued approval for this indication for rucaparib may be contingent upon verification of progression-free survival in the ongoing confirmatory TRITON3 trial (NCT02975934), which is a randomized, controlled phase 3 trial evaluating rucaparib 600 mg twice daily versus physician’s choice of treatment in patients with mCRPC and a deleterious germline or somatic BRCA1, BRCA2, or ATM mutation.

**Pembrolizumab**

FDA approval of pembrolizumab was supported by the Phase 2 KEYNOTE-158 study. The trial included a total of 233 previously treated participants with MSI-H solid tumors, 6 of whom had prostate cancer. In the full cohort, the ORR was 34.3% (95% CI, 28.3% to 40.8%). Median progression-free survival (PFS) was 4.1 months (95% CI, 2.4 to 4.9 months) and median OS was 23.5 months (95% CI, 13.5 months to not reached). Treatment-related adverse events occurred in 151 patients (64.8%).

**Section Summary: Biomarker Testing Using Tissue Biopsy to Select Targeted Treatment**

Clinical trials have demonstrated clinical benefit when testing was used to identify individuals for treatment with FDA-approved therapies.

**Supplemental Information**

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

**Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

**American Society of Clinical Oncology**

In 2022, the American Society of Clinical Oncology (ASCO) published a provisional clinical opinion on the appropriate use of tumor genomic testing in patients with metastatic or advanced solid tumors. The opinion notes the following:

**PCO 1.1.** Genomic testing should be performed for patients with metastatic or advanced solid tumors with adequate performance status in the following 2 clinical scenarios:
When there are genomic biomarker–linked therapies approved by regulatory agencies for their cancer.

When considering a treatment for which there are specific genomic biomarker-based contraindications or exclusions (strength of recommendation: strong).

PCO 1.2.1. For patients with metastatic or advanced solid tumors, genomic testing using multigene genomic sequencing is preferred whenever patients are eligible for a genomic biomarker–linked therapy that a regulatory agency has approved (strength of recommendation: moderate).

PCO 1.2.2. Multigene panel–based genomic testing should be used whenever more than one genomic biomarker is linked to a regulatory agency–approved therapy (strength of recommendation: strong).

PCO 2.1. Mismatch repair deficiency status (dMMR) should be evaluated on patients with metastatic or advanced solid tumors who are candidates for immunotherapy. There are multiple approaches, including using large multigene panel-based testing to assess microsatellite instability (MSI). Consider the prevalence of dMMR and/or MSI-H status in individual tumor types when making this decision (strength of recommendation: strong).

PCO 2.2. When tumor mutational burden (TMB) may influence the decision to use immunotherapy, testing should be performed with either large multigene panels with validated TMB testing or whole-exome analysis (strength of recommendation: strong).

PCO 4.1. Genomic testing should be considered to determine candidacy for tumor-agnostic therapies in patients with metastatic or advanced solid tumors without approved genomic biomarker–linked therapies (strength of recommendation: moderate).

National Comprehensive Cancer Network
Germline Testing
The current National Comprehensive Cancer Network (NCCN) guidelines for prostate cancer are version 4.2022.3. Guidelines are updated frequently; refer to the source for the most current recommendations.

The Principles of Genetics section (PROS-B) provides appropriate scenarios for germline genetic testing in individuals with a personal history of prostate cancer.

Germline testing is recommended in patients with a personal history of prostate cancer in the following scenarios related to the tumor: metastatic, regional (node-positive), very-high risk localized, high-risk localized prostate cancer.

Germline testing may be considered in patients with a personal history of prostate cancer in the following scenarios: intermediate-risk prostate cancer with intraductal/cribriform histology.

Somatic Testing
Tumor testing for alterations in homologous recombination DNA repair genes, such as BRCA1, BRCA2, ATM, PALB2, FANCA, RAD51D, CHEK2, and CDK12, is recommended in patients with metastatic prostate cancer. This testing can be considered in patients with regional prostate cancer.

Tumor testing for microsatellite instability–high (MSI-H) or dMMR is recommended in patients with metastatic castration-resistant prostate cancer and may be considered in patients with regional or castration-naïve metastatic prostate cancer. TMB testing may be considered in patients with metastatic castration-resistant prostate cancer.
Tumor Specimen and Assay Considerations
The panel strongly recommends a metastatic biopsy for histologic and molecular evaluation. When unsafe or unfeasible, plasma ctDNA assay is an option, preferably collected during biochemical (PSA) and/or radiographic progression in order to maximize diagnostic yield. Caution is needed when interpreting ctDNA-only evaluation due to potential interference from clonal hematopoiesis of indeterminate potential (CHIP), which can result in a false-positive biomarker signal.

DNA analysis for MSI and immunohistochemistry (IHC) for MMR are different assays measuring different biological effects caused by dMMR function. If MSI is used, testing using a next-generation sequencing (NGS) assay validated for prostate cancer is preferred. The preferred method of selecting patients for rucaparib treatment is somatic analysis of BRCA1 and BRCA2 using a ctDNA sample.

Post-Test Considerations
Post-test genetic counseling is recommended if pathogenic/likely pathogenic variant (mutation) identified in any gene that has clinical implications if also identified in (e.g., BRCA1, BRCA2, ATM germline, PALB2, CHEK2, MLH1, MSH2, MSH6, PMS2). Post-test genetic counseling to assess for the possibility of Lynch syndrome is recommended if MSI-H or dMMR is found.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials
<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02975934*</td>
<td>TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency</td>
<td>405</td>
<td>Mar 2023</td>
</tr>
<tr>
<td>NCT04019964</td>
<td>Nivolumab as a Non-Castrating Therapy for MMR-deficient and CDK12- Altered Prostate Cancer With PSA Recurrence After Local Therapy</td>
<td>15</td>
<td>Jan 2025</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
* Denotes industry-sponsored or cosponsored trial.

References


**Documentation for Clinical Review**

Please provide the following documentation:
- History and physical and/or consultation notes including:
  - Clinical findings (i.e., pertinent symptoms and duration)
  - Comorbidities
  - Activity and functional limitations
  - Family history, if applicable
• Reason for procedure/test/device, when applicable
• Pertinent past procedural and surgical history
• Pertinent past and present diagnostic testing and results
• Prior pertinent treatments, duration, and response
• Treatment plan (i.e., surgical or medication intervention)
• Consultation and medical clearance report(s), when applicable
• Radiology report(s) and interpretation (i.e., MRI, CT, US)

Post Service (in addition to the above, please include the following):
• Results/reports of tests performed
• Procedure report(s)
• New medications prescribed

Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.

The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>81162</td>
<td>BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis (i.e., detection of large gene rearrangements)</td>
</tr>
<tr>
<td></td>
<td>81301</td>
<td>Microsatellite instability analysis (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) of markers for mismatch repair deficiency (e.g., BAT25, BAT26), includes comparison of neoplastic and normal tissue, if performed</td>
</tr>
<tr>
<td></td>
<td>0037U</td>
<td>Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden (FoundationOne CDx™ (F1CDx))</td>
</tr>
<tr>
<td></td>
<td>0129U</td>
<td>Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis and deletion/duplication analysis panel (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53) BRCAPlus</td>
</tr>
</tbody>
</table>

HCPCS

None

Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/01/2022</td>
<td>New policy.</td>
</tr>
</tbody>
</table>
**Definitions of Decision Determinations**

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member’s illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

**Prior Authorization Requirements and Feedback (as applicable to your plan)**

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member’s health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member’s eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 350708 or visit the provider portal at [www.blueshieldca.com/provider](http://www.blueshieldca.com/provider).

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: MedPolicy@blueshieldca.com

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must
be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.
## Appendix A

### POLICY STATEMENT

<table>
<thead>
<tr>
<th>BEFORE</th>
<th>AFTER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Prostate Cancer (BRCA1/2, Homologous Recombination Repair Gene Alterations, Microsatellite Instability/Mismatch Repair, Tumor Mutational Burden)</strong> 2.04.155</td>
<td><strong>Germline and Somatic Biomarker Testing for Targeted Treatment and Immunotherapy in Prostate Cancer (BRCA1/2, Homologous Recombination Repair Gene Alterations, Microsatellite Instability/Mismatch Repair, Tumor Mutational Burden)</strong> 2.04.155</td>
</tr>
<tr>
<td><strong>Policy Statement:</strong></td>
<td><strong>Policy Statement:</strong></td>
</tr>
<tr>
<td>I. Germline <em>BRCA1</em>/2 variant analysis for individuals with metastatic castrate-resistant prostate cancer (mCRPC; See Policy Guidelines) to select treatment with FDA-approved targeted therapies or immunotherapy may be considered <strong>medically necessary</strong>.</td>
<td>I. Germline <em>BRCA1</em>/2 variant analysis for individuals with metastatic castrate-resistant prostate cancer (mCRPC; See Policy Guidelines) to select treatment with FDA-approved targeted therapies or immunotherapy may be considered <strong>medically necessary</strong>.</td>
</tr>
<tr>
<td>II. All other uses of germline <em>BRCA1</em>/2 variant analysis to guide prostate cancer targeted therapy or immunotherapy are considered <strong>investigational</strong>.</td>
<td>II. All other uses of germline <em>BRCA1</em>/2 variant analysis to guide prostate cancer targeted therapy or immunotherapy are considered <strong>investigational</strong>.</td>
</tr>
<tr>
<td>III. Somatic testing using tissue biopsy for homologous recombination repair (HRR) gene alterations (<em>BRCA1</em>, <em>BRCA2</em>, <em>ATM</em>, <em>BARD1</em>, <em>BRIP1</em>, <em>CDK12</em>, <em>CHEKI</em>, <em>CHEK2</em>, <em>FANCL</em>, <em>PALB2</em>, <em>RAD51B</em>, <em>RAD51C</em>, <em>RAD51D</em>, and <em>RAD54L</em>) to select treatment for mCRPC with FDA-approved targeted therapies or immunotherapy may be considered <strong>medically necessary</strong>. (Note: Testing for HRR gene mutations is not the same as HRD—Homologous Recombination Deficiency—associated with ovarian cancer) See Policy Guidelines.</td>
<td>III. Somatic testing using tissue biopsy for homologous recombination repair (HRR) gene alterations (<em>BRCA1</em>, <em>BRCA2</em>, <em>ATM</em>, <em>BARD1</em>, <em>BRIP1</em>, <em>CDK12</em>, <em>CHEKI</em>, <em>CHEK2</em>, <em>FANCL</em>, <em>PALB2</em>, <em>RAD51B</em>, <em>RAD51C</em>, <em>RAD51D</em>, and <em>RAD54L</em>) to select treatment for mCRPC with FDA-approved targeted therapies or immunotherapy may be considered <strong>medically necessary</strong>. (Note: Testing for HRR gene mutations is not the same as HRD—Homologous Recombination Deficiency—associated with ovarian cancer) See Policy Guidelines. For comprehensive tumor testing panels, see Blue Shield of California Medical Policy: Oncology: Molecular Analysis Of Solid Tumors And Hematologic Malignancies.</td>
</tr>
<tr>
<td>IV. All other uses of somatic testing for HRR gene alterations to guide prostate cancer targeted therapy or immunotherapy are considered <strong>investigational</strong>.</td>
<td>IV. All other uses of somatic testing for HRR gene alterations to guide prostate cancer targeted therapy or immunotherapy are considered <strong>investigational</strong>.</td>
</tr>
<tr>
<td>V. Tumor testing for microsatellite instability (MSI) or deficient mismatch repair (dMMR; <em>MSH2</em>, <em>MSH6</em>, <em>PMS2</em> and <em>MLH1</em>) to select</td>
<td>V. Tumor testing for microsatellite instability (MSI) or deficient mismatch repair (dMMR; <em>MSH2</em>, <em>MSH6</em>, <em>PMS2</em> and <em>MLH1</em>) to select</td>
</tr>
</tbody>
</table>

Reproduction without authorization from Blue Shield of California is prohibited
<table>
<thead>
<tr>
<th>POLICY STATEMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BEFORE</strong></td>
</tr>
<tr>
<td><strong>Red font: Verbiage removed</strong></td>
</tr>
<tr>
<td>treatment for unresectable or metastatic prostate cancer with FDA-approved targeted therapies or immunotherapy (e.g., pembrolizumab/Keytruda). may be considered <em>medically necessary</em>. See Policy Guidelines.</td>
</tr>
<tr>
<td>VI. All other uses of tumor testing for MSI or dMMR to guide prostate cancer targeted therapy or immunotherapy are considered <strong>investigational</strong>.</td>
</tr>
<tr>
<td>VII. <em>BRCA1/2 and ATM</em> variant analysis using ctDNA (liquid biopsy) for individuals with mCRPC to select treatment with FDA-approved targeted therapies may be considered <em>medically necessary</em>. (Note: most liquid biopsies are larger panels and individual gene testing is not available, so a panel including these 3 genes can be approved for this purpose).</td>
</tr>
<tr>
<td>VIII. All other uses of biomarker testing with ctDNA (liquid biopsy) to guide prostate cancer targeted therapy or immunotherapy is considered <strong>investigational</strong> (see Policy Guidelines). Testing for other variants may become available between policy updates.</td>
</tr>
</tbody>
</table>